CD276 [B7-H3] (mouse):Fc (mouse) (rec.) (non-lytic)

B7-H3; B7 Homolog 3

32160000

<0.001EU/µg protein (LAL test; Lonza).

solid

Lyophilized from 0.2µm-filtered solution in PBS.

Avoid freeze/thaw cycles.Centrifuge lyophilized vial before opening and reconstitution.

Recombinant Protein. The extracellular domain of mouse CD276 [B7-H3] (aa 30-248) is fused to the N-terminus of the Fc region of mutant mouse IgG2a. Source/Host: HEK 293 cells. Endotoxin: <0.001EU/µg protein (LAL test; Lonza). Lyophilized from 0.2µm-filtered solution in PBS. CD276 (B7-H3) is a member of the B7/CD28 superfamily of costimulatory molecules serving as an accessory modulator of T cell response. B7 family molecules, which are expressed on antigen-presenting cells and display extracellular regions containing immunoglobulin (Ig) variable (V)- and constant (C)-like domains, are known to modulate T cell receptor (TCR)-mediated T cell activation by providing co-signals that are either stimulatory or inhibitory. B7-H3 provides a stimulatory signal to T cells. However, recent studies suggest a negative regulatory role for B7-H3 in T cell responses. B7-H3 inhibited T cell proliferation mediated by antibody to T cell receptor or allogeneic antigen-presenting cells. B7-H3 is a negative regulator that preferentially affects T(H)1 responses. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. Recently, B7-H3 expression has also been found in a variety of different human cancers, including prostate cancer, clear cell renal cell carcinoma (ccRCC), non-small-cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, ovarian cancer, colorectal cancer (CRC) and urothelial cell carcinoma. B7-H3 was expressed in some human cancers and correlated with poor outcome of cancer patients.

NP_598744.1

Negative Control Protein: Fc (mouse) IgG2a Control (rec.). Non-lytic: Mutations to the complement (C1q) and FcgR I binding sites of the IgGs Fc fragment render the proteins incapable of antibody directed cytotoxicity (ADCC) and complement directed cytotoxicity (CDC).

Plastic Vial

CD276 (B7-H3) is a member of the B7/CD28 superfamily of costimulatory molecules serving as an accessory modulator of T cell response. B7 family molecules, which are expressed on antigen-presenting cells and display extracellular regions containing immunoglobulin (Ig) variable (V)- and constant (C)-like domains, are known to modulate T cell receptor (TCR)-mediated T cell activation by providing co-signals that are either stimulatory or inhibitory. B7-H3 provides a stimulatory signal to T cells. However, recent studies suggest a negative regulatory role for B7-H3 in T cell responses. B7-H3 inhibited T cell proliferation mediated by antibody to T cell receptor or allogeneic antigen-presenting cells. B7-H3 is a negative regulator that preferentially affects T(H)1 responses. B7-H3 may play an important role in muscle-immune interactions, providing further evidence of the active role of muscle cells in local immunoregulatory processes. Recently, B7-H3 expression has also been found in a variety of different human cancers, including prostate cancer, clear cell renal cell carcinoma (ccRCC), non-small-cell lung cancer (NSCLC), pancreatic cancer, gastric cancer, ovarian cancer, colorectal cancer (CRC) and urothelial cell carcinoma. B7-H3 was expressed in some human cancers and correlated with poor outcome of cancer patients.

>98% (SDS-PAGE)

The extracellular domain of mouse CD276 [B7-H3] (aa 30-248) is fused to the N-terminus of the Fc region of mutant mouse IgG2a.

HEK 293 cells

Fc

Non-hazardous

Other Proteins

12352202

Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.